These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 9372886

  • 1. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
    Malmberg I, Persson U, Ask A, Tennvall J, Abrahamsson PA.
    Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
    [Abstract] [Full Text] [Related]

  • 2. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD, Crook JM, Lukka H.
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [Abstract] [Full Text] [Related]

  • 3. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL.
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [Abstract] [Full Text] [Related]

  • 4. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population.
    Sennfält K, Carlsson P, Thorfinn J, Frisk J, Henriksson M, Varenhorst E.
    Scand J Urol Nephrol; 2003 Jan; 37(3):226-31. PubMed ID: 12775282
    [Abstract] [Full Text] [Related]

  • 5. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG, Preston DF, Schiefelbein M, Baxter KG.
    JAMA; 1995 Aug 02; 274(5):420-4. PubMed ID: 7542352
    [Abstract] [Full Text] [Related]

  • 6. The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma.
    Sherman EJ, Pfister DG, Ruchlin HS, Rubin DM, Radzyner MH, Kelleher GH, Slovin SF, Kelly WK, Scher HI.
    Cancer; 2001 Feb 15; 91(4):841-53. PubMed ID: 11241254
    [Abstract] [Full Text] [Related]

  • 7. Cost of radiotherapy in Sweden.
    Acta Oncol; 1996 Feb 15; 35 Suppl 6():57-71. PubMed ID: 9154086
    [Abstract] [Full Text] [Related]

  • 8. The changing costs of radiation treatment for early prostate cancer in Ontario: a comparison between conventional and conformal external beam radiotherapy.
    Poon I, Pintilie M, Potvin M, McGowan T.
    Can J Urol; 2004 Feb 15; 11(1):2125-32. PubMed ID: 15003151
    [Abstract] [Full Text] [Related]

  • 9. Prostate cancer--prevalence-based healthcare costs.
    Norlund A, Alvegård T, Lithman T, Merlo J, Noreen D.
    Scand J Urol Nephrol; 2003 Feb 15; 37(5):371-5. PubMed ID: 14594683
    [Abstract] [Full Text] [Related]

  • 10. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
    De Ruysscher D, Spaas P, Specenier P.
    Acta Urol Belg; 1996 Sep 15; 64(3):13-9. PubMed ID: 8946776
    [Abstract] [Full Text] [Related]

  • 11. Bone pain palliation with 85Sr therapy.
    Giammarile F, Mognetti T, Blondet C, Desuzinges C, Chauvot P.
    J Nucl Med; 1999 Apr 15; 40(4):585-90. PubMed ID: 10210217
    [Abstract] [Full Text] [Related]

  • 12. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
    Porter AT, McEwan AJ.
    Semin Oncol; 1993 Jun 15; 20(3 Suppl 2):38-43. PubMed ID: 7684865
    [Abstract] [Full Text] [Related]

  • 13. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB, Yan WL, Dai JC, Xu F, Yuan Q, Shi HH.
    Zhonghua Nan Ke Xue; 2008 Sep 15; 14(9):819-22. PubMed ID: 18998467
    [Abstract] [Full Text] [Related]

  • 14. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N.
    J Nucl Med; 1999 Feb 15; 40(2):256-61. PubMed ID: 10025832
    [Abstract] [Full Text] [Related]

  • 15. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ.
    J Nucl Med; 2000 Jun 15; 41(6):1021-4. PubMed ID: 10855628
    [Abstract] [Full Text] [Related]

  • 16. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG, Preston DF, Baxter KG, Dusing RW, Spicer JA.
    Semin Oncol; 1993 Jun 15; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [Abstract] [Full Text] [Related]

  • 17. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL, Powe JE, Porter AT.
    J Nucl Med; 1992 Jul 15; 33(7):1316-23. PubMed ID: 1613572
    [Abstract] [Full Text] [Related]

  • 18. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M, Buchali K, Pink V, Lips H.
    Nuklearmedizin; 1992 Mar 15; 31(2):48-52. PubMed ID: 1373485
    [Abstract] [Full Text] [Related]

  • 19. Cumulative cost pattern comparison of prostate cancer treatments.
    Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll PR.
    Cancer; 2007 Feb 01; 109(3):518-27. PubMed ID: 17186528
    [Abstract] [Full Text] [Related]

  • 20. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
    Altman GB, Lee CA.
    Oncol Nurs Forum; 1996 Apr 01; 23(3):523-7. PubMed ID: 8801513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.